stoxline Quote Chart Rank Option Currency Glossary
Celldex Therapeutics, Inc. (CLDX)
36.43  0.42 (1.17%)    06-13 16:00
Open: 35.99
High: 36.8382
Volume: 391,983
Pre. Close: 36.01
Low: 35.69
Market Cap: 2,401(M)
Technical analysis
2024-06-13 4:42:21 PM
Short term     
Mid term     
Targets 6-month :  44.68 1-year :  49.02
Resists First :  38.25 Second :  41.97
Pivot price 34.8
Supports First :  32.25 Second :  26.83
MAs MA(5) :  35.58 MA(20) :  35.68
MA(100) :  39.6 MA(250) :  34.82
MACD MACD :  -1 Signal :  -1.3
%K %D K(14,3) :  57.2 D(3) :  49
RSI RSI(14): 50.2
52-week High :  53.18 Low :  22.11
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLDX ] has closed below upper band by 18.7%. Bollinger Bands are 40.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 36.88 - 37.02 37.02 - 37.17
Low: 35.32 - 35.49 35.49 - 35.66
Close: 36.16 - 36.42 36.42 - 36.68
Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Headline News

Tue, 11 Jun 2024
Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ... - Yahoo Finance UK

Tue, 11 Jun 2024
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Tue, 11 Jun 2024
Celldex initiated to outperform at Wolfe on barzolvolimab for skin disease (NASDAQ:CLDX) - Seeking Alpha

Tue, 11 Jun 2024
Celldex Therapeutics, Inc. (NASDAQ:CLDX) VP Elizabeth Crowley Sells 15,000 Shares - MarketBeat

Sun, 09 Jun 2024
TD Asset Management Inc Has $2.08 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

Fri, 07 Jun 2024
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 66 (M)
Held by Insiders 6.571e+007 (%)
Held by Institutions 0.3 (%)
Shares Short 6,750 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.4712e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -26 %
Return on Assets (ttm) 30.7 %
Return on Equity (ttm) -15.8 %
Qtrly Rev. Growth 6.07e+006 %
Gross Profit (p.s.) -57.08
Sales Per Share -17.28
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -119 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -2.11
Price to Cash Flow 4.21
Stock Dividends
Dividend 0
Forward Dividend 6.62e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android